Serono Integrity Agreement Requires Monitoring Off-Label Use Discussions
Executive Summary
Serono must provide the HHS Inspector General with annual reports of detailing interactions in which sales reps discuss or distribute information about off-label uses
You may also be interested in...
Schering Integrity Agreement Enhances Off-Label Promotion Monitoring
Schering-Plough will be required to implement new monitoring programs to identify and correct potential off-label promotion of certain products by its specialty field sales representatives under an addendum to a 2004 corporate integrity agreement with the HHS Office of Inspector General
Schering Integrity Agreement Enhances Off-Label Promotion Monitoring
Schering-Plough will be required to implement new monitoring programs to identify and correct potential off-label promotion of certain products by its specialty field sales representatives under an addendum to a 2004 corporate integrity agreement with the HHS Office of Inspector General
Serostim $704 Mil. Settlement Is Largest For Off-Label Marketing Case
Serono's $704 mil. settlement over Serostim promotional practices marks the largest penalty ever paid by a pharmaceutical manufacturer to resolve civil and criminal investigations into off-label marketing